Skip to main content

Table 1 Characteristics of the included RCTs

From: Influence of sugammadex versus neostigmine for neuromuscular block reversal on the incidence of postoperative pulmonary complications: a meta-analysis of randomized controlled trials

Study Country Design Patients and surgeries Sample size Mean age Male Neuromuscular blocking agent Sugammadex dose Neostigmine dose Secondary PPCs reporteda
      years %     
Schaller et al., 2010 Germany R, DB ASA I–III, various surgery type 94 42 54 Rocuronium 0.0625, 0.125, 0.25, 0.5, or 1.0 mg/kg 5, 8, 15, 25, or 40 μg/kg A
Geldner et al., 2012 Germany R, DB ASA I–III, laparoscopic surgery 133 51 31 Rocuronium 4 mg/kg 50 μg/kg A
Carron et al., 2013 Italy R ASA I–III, obese patients for laparoscopic removal of adjustable gastric banding 40 43 30 Rocuronium 4 mg/kg 70 μg/kg A
Koyuncu 2014 Turkey R, DB ASA I–II, extremity surgery 100 27 54 Rocuronium 2 mg/kg 70 μg/kg A
Brueckmann et al., 2015 USA R, DB ASA I–III, elective laparoscopic or open abdominal surgery 151 57 60 Rocuronium 2 or 4 mg/kg 17.1–84.8 μg/kg A, B
Unal et al., 2015 Turkey R ASA I–II, surgery for OSA 74 46 NR Rocuronium 2 mg/kg 40 μg/kg A
Hakimoglu et al., 2016 Turkey R ASA I–II, arthroscopic surgery 60 34 65 Rocuronium 4 mg/kg 50 μg/kg A
Loh 2017 Malaysia R, DB ASA I–III, various surgery type 120 44 48 Rocuronium 2 mg/kg 20 μg/kg A
Yagan et al., 2017 Turkey R, SB ASA I–II, various surgery type 98 40 65 Rocuronium 2 mg/kg 50 μg/kg A
Alday et al., 2019 Spain R, SB ASA I–IV, major abdominal surgery 126 68 51 Rocuronium 4 mg/kg 40 μg/kg A, B, C
Claroni et al., 2019 Italy R, DB ASA I–III, robot-assisted radical cystectomy for bladder cancer 109 62 83 Rocuronium 2 mg/kg 40 μg/kg A
Togioka et al., 2020 USA R, OL ASA I–IV, various surgery type 200 75 46 Rocuronium 2 mg/kg 70 μg/kg A, B, C, D
Lee et al., 2020 South Korea R, SB ASA I–II, elective laparoscopic cholecystectomy 73 56 48 Rocuronium 4 mg/kg 40 μg/kg A
Ba et al., 2020 China R ASA I–II, radical resection of lung cancer under thoracoscope 100 50 51 Rocuronium 2 mg/kg 2 mg A
  1. RCTrandomized controlled trial; R randomized; DB double-blind; SB single-blind; OL open-label; ASA American Society of Anesthesiology; OSA obstructive sleep apnea.
  2. aIndicators for secondary PPCs: A, respiratory failure; B, respiratory infection; C, atelectasis; and D, pneumothorax